Best of ASCO - 2014 Annual Meeting

 

Welcome

Central Nervous System Tumors

Central Nervous System Tumors

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A critical appraisal of the quality of glioma imaging guidelines using the AGREE II tool: A EuroAIM initiative.

Sotirios Bisdas

e13553

A gene signature of response to radiotherapy in patients with grade II-III oligodendrogliomas.

Elizabeth Moyal

2041

A phase I study of convection-enhanced delivery of 124I-8H9 radio-labeled monoclonal antibody in children with diffuse intrinsic pontine glioma: An update with dose-response assessment.

Mark M. Souweidane

2008

A phase I study of MGMT-P140K transfected hematopoetic progenitor cells (HPC) combined with TMZ/O6BG dose escalation for newly diagnosed, MGMT unmethylated glioblastoma: Tolerance and evidence of survival benefit.

Andrew E. Sloan

2062

A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.

Ingo K. Mellinghoff

2003

A phase I/II study of nivolumab plus or minus ipilimumab in combination with multifraction stereotactic radiosurgery for recurrent high-grade radiation-relapsed meningioma.

Jiayi Huang

TPS2073

A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642).

Sani Haider Kizilbash

TPS2075

A preliminary comprehensive molecular-based nomogram for individualized estimation of survival in patients with newly diagnosed glioblastoma utilizing global microRNA expression data.

Denise Fabian

2044

A prospective study on the circulation and central nervous system after primary central nervous system B cell lymphoma treatment with rituximab.

Tongyu Lin

e13518

A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).

Mustafa Khasraw

2011

A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma.

Jiayi Huang

2033

Aberrant miRNA expression in glioma.

Anton Pushkin

e13506

Absolute lymphocyte count in patients with glioblastoma treated with temozolomide chemoradiation.

Anas Saeed Bamashmos

e13564

Access to clinical trials, multidisciplinary environment, and health care providers by facility type and outcomes of patients with newly diagnosed glioblastoma using SEER-Medicare dataset.

Ping Zhu

e13576

Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality.

Simone Leyden

e13524

Adjuvant chemotherapy to improve survival in average-risk adult medulloblastoma patients: Long-term results.

Giuseppe Lamberti

2037

Albumin levels and Prognostic Nutritional Index in glioblastoma.

Anas Saeed Bamashmos

e13567

Analysis of the EF-14 phase III trial reveals that tumor treating fields alter progression patterns in glioblastoma.

Suriya A. Jeyapalan

2055

Are patients with oligodendroglioma at higher risk for radiation neurotoxicity?

Haroon Ahmad

2061

Assessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University.

Hannah Rinehardt

e13554

Assessment of neurocognitive function in illiterate patients of high-grade glioma treated with chemoradiation.

Monica Malik

e13543

Avelumab in newly diagnosed glioblastoma multiforme: The SEJ study.

Francois Henri Jacques

e13571

Barriers to accrual and enrollment in brain tumor trials.

Eudocia Quant Lee

2024

Bevacizumab-associated intracerebral hemorrhage in patients with CNS malignancy: A single-center retrospective cohort study.

Nathan Clarke

e13509

BRAFv600e mutated gliomas: From biology to radiology and treatments.

Benoit Lhermitte

e13552

Cancer differentiation analysis technology as a novel technology for cerebral cancer screening.

Hongmei Tao

2040

Carbon ion reirradiaton for patients with malignant gliomas: Toxicity and first results of the prospective dose-escalation phase I/II CINDERELLA trial.

Stephanie E Combs

2059

Circulating endothelial cells: Prognostic value in patients with glioblastoma.

María Ángeles Vaz Salgado

e13517

Clinical characteristics, treatment (Tx) patterns, and overall survival (OS) in advanced (Adv) NSCLC patients (Pts) with and without brain metastases (BM).

Emily Nash Nash Smyth

2035

Clinical efficacy of tumor-treating fields for newly diagnosed glioblastoma.

Yang Liu

2046

Comparison of two dose calculation methods of intra-arterial carboplatin in the treatment of recurrent glioblastoma multiforme.

Brigitte Boilard

e13503

Correlation of systemic and local inflammation with survival prognosis in glioma patients.

Pegah Mir Seyed Nazari

2052

DDR1 may be a good biomarker for brain tumors.

Dilek Erdem

e13557

De novo malignancy in recipients of solid organ transplant from donors with intracranial cancer.

Katie Carsky

e13507

Decision making in surveillance of high-grade gliomas using perfusion MRI as adjunct to conventional MRI and artificial intelligence.

Sotirios Bisdas

2054

Detection of targetable somatic alterations in glioblastoma (GBM) and clinical impact.

Michael Fusco

2058

DGM1 may serve as a novel genetic biomarker of response to enzastaurin in glioblastoma.

Nicholas A. Butowski

2023

Effect of a novel long-acting interleukin-7 agonist, NT-I7, on survival in mouse models of glioma.

Jian Li Campian

e13516

Effect of grade on survival in IDH-mutant grade II and grade III gliomas.

Giuseppe Lamberti

2036

Effect of SSH1/SSH2 expression changes by shRNA in glioma cell lines on response to radiotherapy and cofilin-1 reactivation.

Hong Xiao

e13505

Efficacy and safety of selinexor in recurrent glioblastoma.

Andrew B. Lassman

2005

Efficacy of a novel potent and high water-soluble selective PARP inhibitor CVL218 in glioma.

Steve Shen

e13539

Efficacy of re-irradiation with carbon ions (RiCi) in patients with recurrent high-grade glioma (rHGG) compared to the standard re-irradiation with photons (RiP): The reference multicenter cohort of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).

Maximilian Knoll

2057

EGFR amplification predicted selective sensitivity to PARP inhibitors with high PARP-DNA trapping potential in human GBM.

W. K. Alfred Yung

2047

EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.

Patrick Roth

TPS2072

Epidemiologic and histologic characteristics of central nervous system lesions: A 20-year experience of a single institution in Lebanon.

Roland Eid

e13544

Ethics consultations in patients with neuro-oncologic diseases.

Ugur Sener

e13519

Evaluating the capacity of connectome analysis to predict survival in high-grade astrocytoma.

Rebecca A. Harrison

2049

Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM.

Rimas Vincas Lukas

2053

Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.

E. Antonio Chiocca

2020

Evaluation of prognostic role of inflammatory index in glioblastoma multiforme patients undergoing to concomitant radio-chemotherapy.

Valentina Fausti

e13549

Exploiting metabolic susceptibilities in glioblastoma via glycolytic inhibition and ketogenic therapy.

Frederic Anthony Vallejo

e13558

Factors associated with delays in diagnosis of pediatric, adolescent and young adult patients with central nervous system tumors.

Diane Marie Puccetti

e13532

Factors influencing the intracellular exposure of gemcitabine triphosphate in children with CNS tumors.

Olivia Campagne

e13547

First-in-human phase I trial of the combination of two adenoviral vectors expressing HSV1-TK and FLT3L for the treatment of newly diagnosed resectable malignant glioma: Initial results from the therapeutic reprogramming of the brain immune system.

Pedro R. Lowenstein

2019

Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).

Warren P. Mason

2021

Genomic analysis of paired IDHwt glioblastoma (GB) to reveal recurrent alterations of MPDZ at relapse after radiotherapy and temozolomide (RTCT).

Brice Chanez

e13535

Genomic characterization of lung tumors and metastatic (Met) sites in advanced (Adv) NSCLC.

Melinda D Willard

2014

GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.

Bart Neyns

2034

Glioblastoma evolution pattern under surgery and radio(chemo)therapy (RCHT) to identify novel methylome based glioma subtypes.

Maximilian Knoll

2012

Glioblastoma gene expression subtypes and correlation with clinical, molecular and immunohistochemical characteristics in a homogenously treated cohort: GLIOCAT project.

Estela Pineda

2029

Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).

Hao-Wen Sim

2042

Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients.

Giuseppe Lombardi

2045

High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience.

Matteo Simonelli

e13512

Hyperprogressive disease in patients with recurrent high grade gliomas treated with immune checkpoint inhibitors or other therapies.

Laura Donovan

e13575

Impact of EGFR amplification status in newly diagnosed glioblastoma treated with Stupp protocol.

Addison Barnett

e13569

Impact of next-generation sequencing (NGS) in patients with high grade glioma.

Tariq Zuheir Kewan

e13541

Impact of PET-imaging during treatment planning on outcome in meningioma patients.

Stephanie E Combs

e13542

Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.

Wolfgang Wick

2013

Impact of Zika virus infection in human glioblastoma cell lines.

Andre P. Fay

e13563

Interim results of a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM).

Andrew B. Lassman

2048

Intracerebral immunotherapy for brain tumors.

Guido Carillio

e13522

Leptomeningeal spread of glioma in the molecular era.

Iyad Alnahhas

e13537

Lethality and mitotic activity of T98G glioblastoma cells under the influence of pulsed magnetic fields and ionizing radiation.

Ivan A. Popov

e13511

Lobectomy confers a survival benefit over gross-total resection without lobectomy in cases of primary glioblastoma in non-eloquent area: A retrospective study.

Euihyun Kim

e13561

Longitudinal analysis of quality of life following treatment with asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.

Wolfgang Wick

2022

Low platelet counts in patients with glioblastoma.

Assad Ali

e13565

Male gender is associated with seizure risk in low-grade glioma (LGG) patients.

Jasmin Jo

e13520

MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma.

Dina Randazzo

2039

MGMT status through the ages, literally.

Assad Ali

e13550

Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).

Michael Weller

2056

Multi-parametric MRI as supplement to mRANO criteria for response assessment to MDNA55 in adults with recurrent or progressive glioblastoma.

Diana Roettger

e13559

Mutations of H3.3 and H3.1 in a large cohort of glioma tumors.

Ashley Love Sumrall

e13540

National trends in the use of immunotherapy in the up front management of glioblastoma.

Richard White

e13500

Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): Trial in progress of AMG 596 in patients with recurrent or newly diagnosed disease.

Mark Rosenthal

TPS2071

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.

Annick Desjardins

2060

Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071.

Wolfgang Wick

TPS2076

Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients (PTS) with mismatch repair deficiency (MMRd): An observational study.

Giuseppe Lombardi

2043

Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.

Juanita Suzanne Lopez

2025

Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.

Atsushi Natsume

2004

Phase I study of PD-L1 inhibition with avelumab and laser interstitial thermal therapy in patients with recurrent glioblastoma.

Adilia Hormigo

TPS2074

Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults.

Jing Wu

2031

Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).

David A. Reardon

2032

Phase II trial of palbociclib in recurrent RB-positive anaplastic oligodendroglioma: A Spanish group for research in neurooncology (GEINO) trial.

Juan Manuel Sepulveda-Sanchez

2038

Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter mutation-specific droplet digital PCR assays.

Christine Cordova

2026

Potential biomarkers for targeted and immunotherapy in gliomas.

Jun Wu

e13523

Prospective phase II trial in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with bevacizumab versus bevacizumab alone.

Brandon Konkel

2064

Proteogenomic characterization in glioblastoma multiforme.

Samia Asif

e13521

Quantitative radiographic analysis of phase II and III trials in recurrent glioblastoma treated with VB-111 with or without bevacizumab or bevacizumab monotherapy.

Benjamin M. Ellingson

2018

Radiomics-based identification of peritumoral infiltration in de novo glioblastoma imaging presents targets amenable for potential targeted extended resection: A neurosurgical survey.

Andrew E. Sloan

e13573

Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.

Carmen Balana

2001

Retrospective review for outcomes of IDH mutant, 1p/19q co-deleted gliomas based on initial treatment.

Christopher Ray Trevino

2063

RNA-sequencing and bioinformatic analysis to pre-assess sensitivity to targeted therapeutics in recurrent glioblastoma.

Ella L Kim

e13533

Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM).

Roy E. Strowd

2027

Safety and pharmacokinetics of BXQ-350 in a phase 1a and 1b trial of solid tumors and high-grade glioma.

Olivier Rixe

e13531

Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.

Katherine B. Peters

e13526

Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.

Martin J. Van Den Bent

2000

Spine stereotactic radiosurgery as a promising modality in patients with metastatic hepatocellular and cholangiocarcinoma.

Olsi Gjyshi

e13551

Stratified monotherapy approach according to MGMT methylation status in elderly patients with glioblastoma.

Mitsuaki Shirahata

2050

Study of a smartphone-based symptom assessment (OurBrainBank) for subjects with glioblastomas.

Jessica Morris

e13574

Study of tumor infiltrating immune CELLS and vasculature in human gliomas: Differences in IDH1/2 mutant versus IDH1/2WT tumors.

Maria Cruz Martin Soberón

2030

SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.

Manmeet Singh Ahluwalia

2016

Survival outcomes in glioma patients with noncanonical IDH mutations: Beyond diagnostic improvements.

Enrico Franceschi

2028

Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to brain tissue using drug-embedded biodegradable nanofibers.

Shih-Jung Liu

e13501

Targeting of CD317 by the immunotoxin HM1.24-ETA’ to allow immunotherapy in glioblastoma patients.

Dorothee Gramatzki

e13560

Targeting the androgen receptor as a novel therapeutic strategy for high-grade gliomas by suppressing glioma cancer stem cells.

Nan Zhao

e13504

The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer: A retrospective study from one single cancer institute.

Weiwei Yan

e13502

The effect of everolimus on CNS penetration and efficacy of dasatinib in the treatment of PDGFRA-driven glioma.

Zachary Miklja

e13508

The impact of Epstein-Barr virus status on primary CNS lymphoma survival.

Isabel P Prado

e13528

The prognosis of diffuse midline glioma H3 K27M mutant.

Donghwan KIM

e13548

The role of postradiation temozolomide in patients with newly diagnosed MGMT methylated glioblastoma.

Yuqing Sun

e13530

The timing of chemoradiotherapy after surgical resection and its impact on overall survival in glioblastoma.

Robert H. Press

2051

The use of metformin to enhance radiation effects on M1 macrophage subtype polarization in bone marrow-derived macrophage in glioblastoma tumor environment.

Fei Wang

e13513

The utility of proton MR spectroscopy in diagnosing B cell lymphoma.

Saif Faiek

e13536

The utility of surgery in butterfly glioblastoma: A case-control study.

Benjamin James Hall

e13529

Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).

Matthias Preusser

2007

Trametinib for aggressive gliomas in adults with neurofibromatosis type 1.

Carlos G Romo

e13562

Treatment monitoring of immunotherapy and targeted therapy using FET PET in patients with melanoma and lung cancer brain metastases: Initial experiences.

Norbert Galldiks

e13525

Treatment of cancer-associated thrombosis after craniotomy.

Oksana V. Katelnitskaya

e13510

Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.

Michael Lim

2017

Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.

Erica Hlavin Bell

2002

Using PIK3CB and connexin-43 inhibition to sensitize pediatric glioblastoma cells to temozolomide.

Farah Shah

e13572

Validation and revision of the RANO Leptomeningeal Metastasis Group scorecard for response assessment.

Emilie Le Rhun

e13546